A Comparison of Patient Adherence and Preference of Packaging Method for Oral Anticancer Agents Using Conventional Pill Bottles versus Daily Pill Boxes
| ISRCTN | ISRCTN74558413 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN74558413 |
| Protocol serial number | N/A |
| Sponsor | Princess Margaret Hospital (Canada) |
| Funder | Dr Lillian Siu's research funds |
- Submission date
- 08/11/2005
- Registration date
- 15/11/2005
- Last edited
- 24/07/2014
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Lillian Siu
Scientific
Scientific
Princess Margaret Hospital
610 University Avenue
Toronto
M5G 2M9
Canada
| Phone | +1 416 946 2911 |
|---|---|
| lillian.siu@uhn.on.ca |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomized cross-over design |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | We hypothesize that a simple, low-tech assistance device, such as daily pill boxes, as compared to conventional pill bottles, will increase the rate of patientsÂ’ adherence to oral chemotherapy. |
| Ethics approval(s) | UHN Research Ethics Board, 02/05/2005, UHN REB 05-0199-CE |
| Health condition(s) or problem(s) studied | Advanced solid tumors |
| Intervention | Daily pill boxes versus conventional pill bottles for packaging |
| Intervention type | Other |
| Primary outcome measure(s) |
Patient adherence was similiar. |
| Key secondary outcome measure(s) |
Patients more satisfied with daily pill boxes than conventional pill bottles. |
| Completion date | 30/06/2005 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 25 |
| Key inclusion criteria | Patients were included in this study if they: 1. Provided informed consent 2. Were capable of reading and writing in English 3. Were greater than 18 years of age with solid tumors 4. Were planned to receive at least 2 consecutive cycles of capecitabine |
| Key exclusion criteria | Patients taking other oral anticancer medications such as temozolomide, tamoxifen and arimidex, were not felt to be suitable for the present study since these oral medications are already dispensed in unit dose packages. |
| Date of first enrolment | 01/04/2005 |
| Date of final enrolment | 30/06/2005 |
Locations
Countries of recruitment
- Canada
Study participating centre
Princess Margaret Hospital
Toronto
M5G 2M9
Canada
M5G 2M9
Canada
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | results | 01/07/2007 | Yes | No |
